Pfizer signs multi-year agreement with Kudos

Kudos, the platform for showcasing research, has been chosen by Pfizer to support the dissemination of the biopharmaceutical company’s scientific publications. Kudos will host clinical summaries and links to related content such as peer-reviewed articles, infographics, conference posters, videos, fact sheets, and more. The first treatment areas to benefit will be Inflammation and Immunology, Internal Medicine, and Vaccines.

Pfizer content will be summarized and showcased alongside prestigious content from Kudos’ partnerships with academic publishers and universities. By centralizing discovery, and guiding audiences on a more curated journey through different content, Kudos will help Pfizer maximize visibility. The Kudos platform includes  a rich suite of metrics including citation counts for publications, views of related content, and audience insights.

Rushi Dave, Publications Specialist at Pfizer, said: “By partnering with Kudos, we’re helping to ensure our clinical data and publications reach more of the right people, at the right time.”

“This partnership reflects a shared ambition to improve the transparency and reach of medical publications,” added Charlie Rapple, co-founder of Kudos. “We are delighted to be supporting Pfizer in accelerating the positive effects of clinical research.”

Do you want to read more content like this? SUBSCRIBE to the Research Information Newsline!